Cardiovascular Systems, Inc. (CSII) Income Statement Analysis

See more : Southeastern Banking Corporation (SEBC) Income Statement Analysis – Financial Results

Complete financial analysis of Cardiovascular Systems, Inc. (CSII) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cardiovascular Systems, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.

You may be interested

Cardiovascular Systems, Inc. (CSII)

Industry: Medical - Devices

Sector: Healthcare

Website: https://www.csi360.com

About Cardiovascular Systems, Inc.

Cardiovascular Systems, Inc., a medical technology company, develops and commercializes solutions to treat peripheral and coronary artery diseases in the United States and internationally. The company offers peripheral artery disease products comprising catheter-based platforms to treat various plaque types in above and below the knee, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. In addition, it offers guidewires, catheters, balloons, embolic protection system, and other OAS support products. Cardiovascular Systems, Inc. has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. The company was formerly known as Shturman Cardiology Systems, Inc. and changed its name to Cardiovascular Systems, Inc. in January 2003. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in Saint Paul, Minnesota.

Metric	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005	2004	2003
Revenue	236.22M	258.97M	236.55M	248.02M	217.04M	204.91M	178.18M	181.54M	136.61M	103.90M	82.49M	78.78M	64.83M	56.46M	58.57M	15.99M	441.00K	834.00K	726.00K	0.00
Cost of Revenue	63.44M	61.13M	48.76M	47.68M	39.48M	39.44M	35.42M	39.52M	31.04M	24.38M	19.22M	16.28M	15.00M	16.19M	0.00	0.00	0.00	0.00	0.00	0.00
Gross Profit	172.78M	197.84M	187.79M	200.34M	177.56M	165.47M	142.76M	142.02M	105.57M	79.52M	63.27M	62.50M	49.83M	40.27M	58.57M	15.99M	441.00K	834.00K	726.00K	0.00
Gross Profit Ratio	73.14%	76.39%	79.39%	80.78%	81.81%	80.75%	80.12%	78.23%	77.28%	76.53%	76.71%	79.34%	76.86%	71.32%	100.00%	100.00%	100.00%	100.00%	100.00%	0.00%
Research & Development	36.72M	41.06M	43.36M	33.46M	26.76M	22.91M	25.93M	30.98M	21.07M	15.22M	11.37M	8.94M	10.28M	14.68M	43.31M	38.30M	29.18M	16.28M	0.00	2.52M
General & Administrative	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Selling & Marketing	0.00	0.00	0.00	167.70M	148.57M	144.10M	162.54M	143.68M	117.99M	86.72M	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
SG&A	170.53M	167.50M	169.97M	167.70M	148.57M	144.10M	162.54M	143.68M	117.99M	86.72M	66.37M	62.37M	62.45M	59.82M	13.02M	12.19M	5.33M	2.99M	0.00	1.28M
Other Expenses	1.34M	1.22M	1.23M	760.00K	-390.00K	-164.00K	53.00K	-162.00K	-706.00K	-671.00K	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Expenses	208.59M	209.78M	214.56M	201.16M	175.33M	167.01M	188.48M	174.66M	139.06M	101.93M	77.74M	71.31M	72.73M	74.50M	56.33M	50.48M	34.51M	19.28M	0.00	3.79M
Cost & Expenses	272.03M	270.91M	263.32M	248.84M	214.81M	206.45M	223.90M	214.18M	170.10M	126.32M	96.96M	87.59M	87.73M	90.69M	56.33M	50.48M	34.51M	19.28M	0.00	3.79M
Interest Income	817.00K	499.00K	1.74M	2.44M	1.33M	383.00K	0.00	0.00	0.00	-1.62M	5.00K	12.00K	402.00K	3.38M	0.00	0.00	0.00	0.00	0.00	0.00
Interest Expense	1.63M	1.74M	1.97M	1.68M	1.72M	500.00K	0.00	23.00K	1.03M	1.35M	2.32M	1.42M	1.44M	2.35M	0.00	0.00	0.00	0.00	0.00	0.00
Depreciation & Amortization	1.34M	1.22M	1.23M	3.45M	3.93M	4.14M	3.92M	2.32M	1.37M	973.00K	872.00K	716.00K	600.00K	470.00K	2.25M	683.00K	1.29M	1.30M	0.00	0.00
EBITDA	-34.46M	-10.72M	-25.54M	-825.00K	2.23M	-1.54M	-35.35M	-32.64M	-33.49M	-22.42M	-14.47M	-8.81M	-22.33M	-35.07M	-963.00K	-39.07M	-32.78M	-16.68M	726.00K	-3.79M
EBITDA Ratio	-14.59%	-4.14%	-10.80%	-0.33%	1.03%	-0.75%	-19.84%	-17.98%	-24.51%	-21.58%	-17.54%	-11.18%	-34.44%	-62.12%	-1.64%	-244.37%	-7,431.97%	-1,999.76%	100.00%	0.00%
Operating Income	-35.81M	-11.93M	-26.77M	-825.00K	-1.70M	-1.54M	-56.08M	-32.64M	-33.49M	-22.42M	-14.47M	-8.81M	-22.90M	-34.23M	2.24M	-34.49M	-34.07M	-18.44M	726.00K	-3.79M
Operating Income Ratio	-15.16%	-4.61%	-11.32%	-0.33%	-0.78%	-0.75%	-31.47%	-17.98%	-24.51%	-21.58%	-17.54%	-11.18%	-35.32%	-60.63%	3.82%	-215.75%	-7,725.17%	-2,211.27%	100.00%	0.00%
Total Other Income/Expenses	-817.00K	-1.24M	-233.00K	760.00K	3.54M	-164.00K	53.00K	-185.00K	-1.80M	-1.62M	-2.32M	0.00	28.00K	1.31M	5.45M	5.26M	399.00K	-797.00K	0.00	0.00
Income Before Tax	-36.62M	-13.17M	-27.01M	-65.00K	1.84M	-1.71M	-56.02M	-32.82M	-35.29M	-24.04M	-15.44M	0.00	-22.87M	-32.93M	7.69M	-29.24M	-33.67M	-19.24M	0.00	0.00
Income Before Tax Ratio	-15.50%	-5.09%	-11.42%	-0.03%	0.85%	-0.83%	-31.44%	-18.08%	-25.83%	-23.14%	-18.72%	0.00%	-35.28%	-58.31%	13.13%	-182.86%	-7,634.69%	-2,306.83%	0.00%	0.00%
Income Tax Expense	310.00K	252.00K	231.00K	190.00K	132.00K	86.00K	6.39M	-2.30M	-333.00K	344.00K	479.00K	1.60M	1.01M	-25.12M	-5.45M	-5.25M	0.00	797.00K	13.95M	3.76M
Net Income	-36.93M	-13.42M	-27.24M	-255.00K	1.71M	-1.79M	-56.02M	-32.82M	-35.29M	-24.04M	-16.79M	-11.13M	-23.90M	-9.11M	7.69M	-29.25M	-33.67M	-19.24M	-13.95M	-3.76M
Net Income Ratio	-15.63%	-5.18%	-11.51%	-0.10%	0.79%	-0.87%	-31.44%	-18.08%	-25.83%	-23.14%	-20.35%	-14.12%	-36.87%	-16.14%	13.13%	-182.94%	-7,634.69%	-2,306.83%	-1,921.49%	0.00%
EPS	-0.94	-0.35	-0.79	-0.01	0.05	-0.06	-1.72	-1.04	-1.25	-1.11	-0.93	-0.70	-1.62	-1.13	2.90	-21.03	-323.00	-257.79	-208.20	-53.01
EPS Diluted	-0.94	-0.35	-0.79	-0.01	0.05	-0.06	-1.72	-1.04	-1.25	-1.11	-0.93	-0.70	-1.62	-1.13	2.80	-21.03	-323.00	-257.79	-208.20	-53.01
Weighted Avg Shares Out	39.23M	38.83M	34.28M	33.54M	33.15M	32.37M	32.54M	31.55M	28.30M	21.69M	18.04M	15.92M	14.75M	8.07M	2.67M	1.39M	104.24K	74.63K	67.00K	70.97K
Weighted Avg Shares Out (Dil)	39.23M	38.83M	34.28M	33.54M	33.61M	32.37M	32.54M	31.55M	28.30M	21.69M	18.04M	15.92M	14.75M	8.07M	2.77M	1.39M	104.24K	74.63K	67.00K	70.97K

New Strong Sell Stocks for December 28th

December 28, 2021zacks.com

DVA, CSII, BYND, AVYA, and GFF have been added to the Zacks Rank #5 (Strong Sell) List on December 28, 2021.

Cardiovascular Systems Recalls Wirion Embolic Protection System

November 26, 2021benzinga.com

Cardiovascular Systems Inc (NASDAQ: CSII) has commenced a voluntary recall of its WIRION Embolic Protection Systems (WIRION). The unused WRN-D6 models of the WIRION device are being recalled due to receiving complaints regarding filter breakage at the time of retrieval.

Cardiovascular Systems, Inc. Initiates Voluntary Recall of WIRION® Embolic Protection System

November 24, 2021businesswire.com

ST. PAUL, Minn.--(BUSINESS WIRE)--Cardiovascular Systems, Inc. (CSI®) (NASDAQ: CSII) has initiated a voluntary recall of unused WIRION Embolic Protection Systems (WIRION) due to complaints of filter breakage during retrieval. CSI has informed all affected healthcare facilities to discontinue use of...